Redwan
(#34642115)
Level 1 Skydancer
Familiar
Daydream Puffer
Click or tap to view this dragon in Predict Morphology.
Energy: 0/50
This dragon’s natural inborn element is Light.
Female Skydancer
Expand the dragon details section.
Collapse the dragon details section.
Personal Style
Apparel
Skin
Scene
Measurements
Length
4.33 m
Wingspan
5.59 m
Weight
759.91 kg
Genetics
Black
Tiger
Tiger
Mulberry
Shimmer
Shimmer
Auburn
Smoke
Smoke
Hatchday
Breed
Eye Type
Level 1 Skydancer
EXP: 0 / 245
STR
4
AGI
5
DEF
4
QCK
9
INT
9
VIT
4
MND
9
Lineage
Biography
from SquishyLiz's Lair
https://www.researchgate.net/profile/Elrashdy_Redwan3
Elrashdy M Redwan
King Abdulaziz University · Department of Biological Science
34.38 · Ph.D
King Abdulaziz University
Department of Biological ScienceJeddah, Saudi Arabia
Current position
Full Professor
Elrashdy M Redwan's Lab
Lab head
Elrashdy M Redwan
107 Research items
14,299 Reads
1,231 Citations
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203937/
'Cell factories for insulin production
Nabih A Baeshen, Mohammed N Baeshen, Abdullah Sheikh, Roop S Bora, Mohamed Morsi M Ahmed,corresponding author Hassan A I Ramadan, Kulvinder Singh Saini, and Elrashdy M Redwan
Author information ► Article notes ► Copyright and License information ► Disclaimer
This article has been cited by other articles in PMC.
Go to:
Abstract
The rapid increase in the number of diabetic patients globally and exploration of alternate insulin delivery methods such as inhalation or oral route that rely on higher doses, is bound to escalate the demand for recombinant insulin in near future. Current manufacturing technologies would be unable to meet the growing demand of affordable insulin due to limitation in production capacity and high production cost. Manufacturing of therapeutic recombinant proteins require an appropriate host organism with efficient machinery for posttranslational modifications and protein refolding. Recombinant human insulin has been produced predominantly using E. coli and Saccharomyces cerevisiae for therapeutic use in human. We would focus in this review, on various approaches that can be exploited to increase the production of a biologically active insulin and its analogues in E. coli and yeast. Transgenic plants are also very attractive expression system, which can be exploited to produce insulin in large quantities for therapeutic use in human. Plant-based expression system hold tremendous potential for high-capacity production of insulin in very cost-effective manner. Very high level of expression of biologically active proinsulin in seeds or leaves with long-term stability, offers a low-cost technology for both injectable as well as oral delivery of proinsulin.
Keywords: Recombinant insulin, E. coli, Yeast, Expression system, Posttranslational modifications, Transgenic plants
https://www.researchgate.net/profile/Elrashdy_Redwan3
Elrashdy M Redwan
King Abdulaziz University · Department of Biological Science
34.38 · Ph.D
King Abdulaziz University
Department of Biological ScienceJeddah, Saudi Arabia
Current position
Full Professor
Elrashdy M Redwan's Lab
Lab head
Elrashdy M Redwan
107 Research items
14,299 Reads
1,231 Citations
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203937/
'Cell factories for insulin production
Nabih A Baeshen, Mohammed N Baeshen, Abdullah Sheikh, Roop S Bora, Mohamed Morsi M Ahmed,corresponding author Hassan A I Ramadan, Kulvinder Singh Saini, and Elrashdy M Redwan
Author information ► Article notes ► Copyright and License information ► Disclaimer
This article has been cited by other articles in PMC.
Go to:
Abstract
The rapid increase in the number of diabetic patients globally and exploration of alternate insulin delivery methods such as inhalation or oral route that rely on higher doses, is bound to escalate the demand for recombinant insulin in near future. Current manufacturing technologies would be unable to meet the growing demand of affordable insulin due to limitation in production capacity and high production cost. Manufacturing of therapeutic recombinant proteins require an appropriate host organism with efficient machinery for posttranslational modifications and protein refolding. Recombinant human insulin has been produced predominantly using E. coli and Saccharomyces cerevisiae for therapeutic use in human. We would focus in this review, on various approaches that can be exploited to increase the production of a biologically active insulin and its analogues in E. coli and yeast. Transgenic plants are also very attractive expression system, which can be exploited to produce insulin in large quantities for therapeutic use in human. Plant-based expression system hold tremendous potential for high-capacity production of insulin in very cost-effective manner. Very high level of expression of biologically active proinsulin in seeds or leaves with long-term stability, offers a low-cost technology for both injectable as well as oral delivery of proinsulin.
Keywords: Recombinant insulin, E. coli, Yeast, Expression system, Posttranslational modifications, Transgenic plants
Click or tap a food type to individually feed this dragon only. The other dragons in your lair will not have their energy replenished.
Feed this dragon Insects.
This dragon doesn't eat Meat.
This dragon doesn't eat Seafood.
Plant stocks are currently depleted.
You can share this dragon on the forums by either copying the browser URL manually, or using bbcode!
Exalting Redwan to the service of the Gladekeeper will remove them from your lair forever. They will leave behind a small sum of riches that they have accumulated. This action is irreversible.
Do you wish to continue?
- Names must be longer than 2 characters.
- Names must be no longer than 16 characters.
- Names can only contain letters.
- Names must be no longer than 16 characters.
- Names can only contain letters.